How Does Remicade Work?

• Infliximab (Remicade) belongs to a class of medications called TNF-alpha inhibitors. These medications work by blocking the activities of cytokine, a cell protein that aggravates inflammation in the joints of RA patients. Evidence suggests that TNF-alpha inhibitors are not only effective in diminishing pain and joint tenderness but may actually help halt the overall advance of RA. If you suffer from the debilitating effects of advancing RA, it is likely your doctor has mentioned the potential benefits of infliximab, or other TNF-alpha inhibitors including adalimumab (Humira) and etanercept (Enbrel).
  
  

What to Expect During Infusion

• Before starting Remicade infusion, inform your doctor of any other medications you are taking, including other TNF-alpha inhibitors. Do not get vaccinated without your doctor's consent. You will also need a tuberculosis check prior to treatment.
  
  Remicade infusion is typically administered in your doctor's office. Infusions are given every two to eight weeks, and each individual treatment takes roughly two hours. During treatment you will be closely monitored by your doctor or a nurse for signs of allergic reaction, including rash, itching, hives, breathing difficulties, dizziness, fainting, seizures, chest pain or swelling of the face, tongue, hands, feet or lower legs. Your doctor will be especially alert for any heart-related distress, since Remicade is particularly capable of worsening these problems. Be sure to communicate any problems as they occur.
  
  

Risks of Remicade Use

• Use of Remicade and other TNF-alpha inhibitors stems from the desire to escape pain and potential disfigurement. This may be especially true because these drugs are quite effective in achieving their treatment objectives. Still, before beginning a course of Remicade infusion, you should fully consider some of the warnings regarding the side effects of TNF-alpha inhibitors.
  
  In 2008, the Food and Drug Administration (FDA) issued two separate warnings to health care professionals regarding TNF-alpha inhibitors, including Remicade. The first notice reported the results of 10 years of monitoring that found a potential link between TNF-alpha inhibitors and cancer development in RA patients under the age of 18. The second notice reported the potential of TNF-alpha inhibitors to block detection of serious fungal infections. In some cases, treatment delays brought about by this masking resulted in death. As of 2009, the results of these findings are still being investigated. Apart from these notices, use of Remicade is associated with increased risks for lymphoma. Sufferers of chronic obstructive pulmonary disorder (COPD) may be particularly at risk. It is important to note, however, that Remicade is still approved for use by the FDA.
  
  To help safeguard yourself during the use of Remicade infusions, consult your doctor in depth regarding the potential for these serious adverse developments.